Supernus Pharmaceuticals, Inc.
SUPN
$48.27
$1.122.38%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -359.44% | 80.61% | -126.78% | -217.20% | 12.97% |
| Total Depreciation and Amortization | 20.55% | 28.20% | 32.75% | 23.40% | 3.09% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 860.48% | 157.23% | 227.48% | 179.65% | 251.21% |
| Change in Net Operating Assets | -124.25% | 56.44% | -901.31% | -523.97% | 495.87% |
| Cash from Operations | -108.22% | 117.41% | -55.27% | -215.22% | 64.31% |
| Capital Expenditure | -24.84% | -- | -100.47% | 35.50% | -610.94% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 125.41% | -151.05% | -309.52% | 545.15% | 37.87% |
| Cash from Investing | 123.18% | -151.50% | -306.00% | 163.25% | 37.01% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 25.85% | 569.44% | 24.43% | 585.76% | 97.47% |
| Repurchase of Common Stock | -91.30% | -36.34% | 96.86% | -109.56% | -4,500.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -389.54% | -- | -- | -- | -- |
| Cash from Financing | -870.05% | 142.60% | 44.75% | 585.14% | -43.61% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -117.03% | 21.29% | -160.87% | 139.72% | 355.15% |